Hims & Hers Health (HIMS) Total Non-Current Liabilities (2020 - 2026)
Hims & Hers Health (HIMS) posted Total Non-Current Liabilities of $1.8 billion for Q1 2026, up 12.85% sequentially from $1.6 billion in Q4 2025, and up 431.74% YoY from $340.0 million in Q1 2025.
Hims & Hers Health (HIMS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Hims & Hers Health has reported Total Non-Current Liabilities for 7 years, with the latest figure at $1.8 billion in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 431.74% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 431.74% YoY) and the FY2025 annual result came in at $1.6 billion, up 594.06% from the prior year.
- Total Non-Current Liabilities climbed to $1.8 billion in Q1 2026 per HIMS's latest filing, from $1.6 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.8 billion in Q1 2026 and troughed at $53.8 million in Q1 2022.
- A 5-year average of $463.6 million and a median of $103.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities slumped 36.06% in 2022, then soared 1008.31% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $54.6 million in 2022, then surged by 78.02% to $97.1 million in 2023, then soared by 137.63% to $230.8 million in 2024, then soared by 594.06% to $1.6 billion in 2025, then increased by 12.85% to $1.8 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.8 billion, $1.6 billion, and $1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Hims & Hers Health | 7.44 Bn | 6.60 Bn | 480.80 Mn | 3.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.30 Bn |
| Mar 31, 2026 | 1.81 Bn |
| Dec 31, 2025 | 1.60 Bn |
| Sep 30, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 340.01 Mn |
| Dec 31, 2024 | 230.82 Mn |
| Sep 30, 2024 | 162.21 Mn |
| Jun 30, 2024 | 118.51 Mn |
| Mar 31, 2024 | 103.60 Mn |
| Dec 31, 2023 | 97.14 Mn |
| Sep 30, 2023 | 85.30 Mn |
| Jun 30, 2023 | 69.81 Mn |
| Mar 31, 2023 | 63.48 Mn |
| Dec 31, 2022 | 54.57 Mn |
| Sep 30, 2022 | 71.63 Mn |
| Jun 30, 2022 | 60.54 Mn |
| Mar 31, 2022 | 53.81 Mn |
| Dec 31, 2021 | 85.34 Mn |
| Sep 30, 2021 | 53.72 Mn |